479690-03-4

Basic information

• Product Name: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-
• CAS NO: 479690-03-4
• Molecular Formula: C23H17FN2O5
• Molecular Weight: 420.397
• Mol File: 479690-03-4.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-(479690-03-4)
• EPA Substance Registry System: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)-(479690-03-4)

Safety Data

• Hazardous Substances Data: 479690-03-4(Hazardous Substances Data)

Usage

General Description

Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(phenylmethoxy)- is a complex chemical compound with a quinoline base and various substituents including 2-fluoro-4-nitrophenoxy, 6-methoxy, and 7-phenylmethoxy groups. Quinoline is a heterocyclic aromatic compound with a wide range of applications including in the production of dyes, pesticides, and pharmaceuticals. The presence of the nitro and fluoro groups in this specific quinoline derivative suggests potential pharmacological activity and may be of interest in the development of novel drugs with specific biological properties. However, further research is required to fully understand and exploit the potential applications of this compound.

Upstream product

• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 516526-45-7 4-(2-fluoro-4-nitrophenoxy)-7-methoxylquinolyl-6-ol 
• 100-44-7 benzyl chloride 
• 205448-29-9 6-methoxy-7-benzyloxy-4(1H)-quinolinone 
• 369-34-6 3,4-difluoronitrobenzene 
• 75665-73-5 1-(2-amino-4-(benzyloxy)-5-methoxyphenyl)ethanone 
• 636-93-1 5-nitroguaiacol 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 403-19-0 2-fluoro-4-nitrophenol 
• 205448-29-9 7-benzyloxy-4-hydroxy-6-methoxyquinoline 
• 205448-28-8 5-{[(3-(benzyloxy)-4-methoxyphenyl)amino]methylene}-2,2-dimethyl-1,3-dioxane-4,6- dione 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 479690-04-5 4-(7-(benzyloxy)-6-methoxyquinolin-4-yloxy)-3-fluorobenzenamine 
• 1394166-11-0 3-fluoro-4-((6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)oxy)aniline 
• 849217-64-7 foretinib 
• 1292258-21-9 N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-methylbenzenesulfonamide 
• 1292258-13-9 N-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethylbenzenesulfonamide 
• 1290538-60-1 {3-[4-(4-amino-2-fluorophenoxy)-6-methoxyquinolin-7-yloxy]propyl}carbamic acid tert-butyl ester 
• 1290538-61-2 3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperidin-1-yl)propoxy]quinolin-4-yloxy}phenylamine 

Relevant articles and documents

QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF

The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the presen

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

Preparation methods of tyrosine kinase inhibitor XJF007 and its intermediate

The invention discloses preparation methods of tyrosine kinase inhibitor XJF007 with a general structural formula (I) and its intermediate. The preparation method of the tyrosine kinase inhibitor XJF007 employs a collecting synthesis strategy of construct